Interventional Strategies for the Superficial Femoral Artery by Gjeka, Rudin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Interventional Strategies for the Superficial Femoral
Artery
Rudin Gjeka
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.76724
Abstract
The incidence of peripheral arterial disease (PAD) is rising due to significant increase in
metabolic disease such as diabetes mellitus, increase in aging population, and tobacco use.
Superficial femoral artery (SFA) disease is the leading cause of peripheral artery disease
and claudication. In the last decades, several technologies/techniques have been devel-
oped for the treatment of SFA atherosclerotic disease including balloon angioplasty, bal-
loon expanding stents, self-expanding stents, drug-eluting balloon, and atherectomy. The
advances made in technology have significantly improved the quality of the balloons, but
they have limitations especially in long and calcified lesions. While the initial studies
using stainless steel stents failed to show any significant difference in outcomes, under-
standing the pathophysiology and improvement in stent technologies has shown signifi-
cant reduction of restenosis by five- to sevenfold when compared to angioplasty alone.
Atherectomy is another modality of plaque modification and treatment, which can be
done as a stand-alone treatment or more commonly combined with PTA and/or stenting.
Finally, several randomized studies and registries have showed that with improvement in
technology, there is significant improvement in long-term outcomes of SFA atherosclerotic
disease.
Keywords: superficial femoral artery angioplasty, superficial femoral artery stenting,
SFA rotational atherectomy, SFA laser atherectomy, SFA directional atherectomy
1. Introduction
The incidence of peripheral arterial disease (PAD) is rising due to significant increase in
metabolic diseases such as diabetes mellitus, increase in aging population and tobacco use.
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PAD is the third cardiovascular cause of morbidity following the coronary artery disease and
stroke.
Superficial femoral artery (SFA) disease is the leading cause of peripheral artery disease and
claudication. According to current estimates, there are over 8 million people affected with PAD
and the numbers are rising. Nearly half of the patients affected from PAD are asymptomatic
and about 20% have claudication [1–4]. Regardless if the patients are symptomatic or not,
patients with PAD have worse quality of life and worse outcomes when compared to people
that do not [5].
Nearly 50 years after the first endovascular intervention of the SFA performed by Charles
Dotter, endovascular intervention of the lower extremity has increased significantly [6]. The
relatively low risk for morbidity andmortality and improvement in technology have seen a high
success rate making the endovascular intervention of the SFA the preferred choice, particularly
in short-segment disease [7]. Nevertheless, the unique biochemical, anatomical, and hemody-
namic forces the SFA is exposed to, makes the endovascular intervention quite challenging.
Rutherford category Characteristic
0 Asymptomatic
1 Mild claudication
2 Moderate claudication
3 Severe claudication
4 Pain at rest
5 Minor tissue loss
6 Major tissue loss
Table 1. Rutherford classification of chronic limb ischemia.
Trans-Atlantic Inter-Society Consensus II classification of femoropopliteal disease
Type lesion Stenosis or occlusion pattern Procedure
A Single stenosis less or equal to 10 cm or occlusion less or equal to 5 cm. Endovascular
B Multiple stenosis or occlusion less or equal to 5 cm or a single severely calcified occlusion
of 5 cm or less.
Single stenosis or occlusion of 15 cm or less, not involving below the knee popliteal
artery.
Single or multiple lesions in conjunction with occluded proximal infra-geniculate vessels
to improve inflow for distal bypass.
Single popliteal artery stenosis.
Endovascular
C Multiple stenosis or occlusion adding to more than 15 cm irrespective of calcification.
Two failed attempts for endovascular revascularization.
Endovascular or
Surgical bypass
D Chronic occlusions of the CFA, more than 20 cm of SFA stenosis, popliteal artery or
proximal trifurcation vessels.
Surgical bypass
CFA = Common Femoral Artery. SFA = Superficial Femoral Artery.
Table 2. Trans-Atlantic inter-society consensus II (TASC II). Classification of the femoropopliteal disease.
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Indications to intervene upon the lower extremities depend on the severity of disease and
symptoms with absolute indications in cases with limb-threatening ischemia with resting pain
and tissue loss (including Rutherford classification class 4–6). Relative indications are not limb
threatening but significantly debilitating and often a reason to intervene upon and include
mainly patients with intermittent claudication (Rutherford class 2 and 3), [8] (Table 1).
Once intervention is indicated, the decision to intervene via endovascular approach rather
than open surgical approach is mainly based upon the Trans-Atlantic inter-Society Consensus
II Classification (TASCII) recommendations [7] (Table 2).
2. Vascular access technique
Like all endovascular interventions, SFA interventions begin with vascular access. The most
common vascular access is the common femoral artery (CFR). In selected cases, brachial artery
can be used as well. For safety purposes and in attempting to reduce complications, the
recommended technique is the ultrasound (US)-guided technique and if possible micropunc-
ture needle can be used as well.
Using the ultrasound permits direct visualization of the artery and its branches. US-guided
access reduces multiple punctures and as such reduces the incidence of arteriovenous fistulas.
US-guided technique is an excellent choice in patients with no palpable pulse, heavily diseased
common femoral artery (CFR), obese patients, and high bifurcation [9].
Puncture using anatomical landmarks is another approach several operators use. The point of
maximal pulsation correlates with the midpoint of the CFA in over 92% of the cases. When the
pulse is difficult to palpate, the midpoint between the anterior superior iliac spine and pubic
tubercle by palpation is used. The groin crease is an unreliable marker and is located distal to
the CFA bifurcation and is located distal to the CFA bifurcation in about three out of four
patients. Fluoroscopy-guided puncture can be used as well, aiming the inner lower third of the
femoral head. The femoral head provides a solid surface for firm compression of the CFA
necessary for hemostasis following arterial puncture [10–12].
Arterial access can be obtained on either side with the contralateral side being the preferred in
most cases. The contralateral access remains the preferred choice as it allows an adequate
working length to image and treat the sequential lesions within the entire target extremity.
Once the access is obtained, a guide wire is introduced with size 0.018–0.035-in depending on
if it is a micropuncture or not. Sheath sizes used for the SFA intervention range from 4 to 7
French. Sheaths protect the access vessel during the catheter intervention and wire exchanges
during a procedure. The smallest size sheath to complete the intervention should be used. A
reverse curved catheter and a 0.035-in guide wire are usually used to crossover the aortic
bifurcation. The guide wire is then advanced to the level of the CFA and at that point allows
to advance a catheter to the distal external iliac artery. At this point, serial lower extremity
angiograms can be performed at the target extremity. Patency of the runoff vessels is very
important to assess prior to intervention. Clinically assessing the presence of pulses is very
important because distal vessels can be occluded secondary to embolization from the SFA
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intervention. In presence of single-vessel runoff, an embolic protection filter can be used prior
to intervention to minimize distal embolic occlusion. Prior to starting intervention, the patient
should be heparinized with an activated clotting time (ACT) of 250 seconds or more [13].
After the patient is anticoagulated, the target SFA lesion must be crossed. This is achieved
using a directional catheter and a 0.035-in wire, usually a hydrophilic wire. The catheter is
usually positioned just proximal to the target lesion providing wire support and pushability
to cross the stenosis. Remaining intraluminal is the preferred technique to cross the lesion,
but it is not possible with a 0.035-in wire. Therefore, an attempt can be made by using a
0.018-inch or a 0.014-inch guide wire and catheter. If there are still difficulties in crossing
the lesion, then a subintimal approach can be attempted. When the reentry with a hydro-
philic wire is not possible, then the use of a reentry device is recommended. Subintimal
angioplasty can be performed effectively with excellent technical success and acceptable
patency [14–16].
3. Balloon angioplasty
Balloon angioplasty remains the most frequently used technique in the treatment of SFA
disease as either primary or adjunctive therapy for stents and other devices. After crossing
the lesion, an appropriate balloon must be selected. There are several balloons that can be used
in different scenarios as we describe later [20].
The noncompliant balloons inflate to a uniform diameter regardless of the amount of pressure
introduced in the balloon. As such, the noncompliant balloons are often preferred because they
are less likely to cause injury to the native vessel and are more effective in treating atheroscle-
rotic lesions. Balloon catheters can be over the wire, and they offer more pushability and often
times are better in crossing tight lesions. Furthermore, these balloons can be used as catheters
as well. Monorail or the rapid exchange balloons are less cumbersome and easier to handle as
they use shorter wires. However, these advantages come at the expense of the pushability, and
crossing a tight lesion with a monorail balloon can be more challenging. The diameter of a
normal SFA segment distal to the lesion is used as a reference to size the angioplasty. To size
the length of the balloon, a radiopaque external ruler is used. The proper length of the balloon
must treat the target lesion without disruption of the normal segment proximal and distal to
the lesion [17].
The nominal pressure of a balloon is the pressure at which the balloon will achieve the
manufacturer’s stated diameter. With noncompliant balloon, increasing the pressure will not
result in increase in diameter, while with compliant or semi-compliant balloons, an increase in
pressure will result in balloon overinflation to a larger diameter. Overinflation and over-sizing
the balloon can cause trauma to the artery or significant dissection. The burst pressure is the
pressure at which 99.9% of the balloon will not rupture. This pressure should not be exceeded.
Balloon can rupture due to overinflation or if the atherosclerotic plaque is heavily calcified.
Balloon rupture can cause embolization of balloon fragments or air embolization if the balloon
is not properly prepped [17, 18].
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When planning on performing only angioplasty without stent placement, longer balloon infla-
tion times are used to stabilize the luminal surface of the arterial segment being treated. The
longer inflation times may reduce a flow-limiting dissection. After the intervention, angiography
is performed; if there is any vessel recoil, persistent stenosis, or a flow-limiting dissection, repeat
angioplasty is recommended. In these circumstances, increase of inflation times is recommended
[17, 19].
Conventional balloons are associated with a high rate of uncontrolled dissections that may
require bailout stenting, particularly in more complex and diffuse SFA lesions. Cutting balloons
are reinforced with microtomes that provide a leading edge to cut through stiff fibrotic lesions at
lower pressures. These types of balloons are suggested instead of using larger diameter balloons
and may be associated with less hemodynamically significant dissections. Studies have shown
that use of cutting balloons have shown better long-term patency in peripheral artery interven-
tions. When there is a persistent residual stenosis of more than 50% or a flow-limiting dissection
after the PTA, provisional stenting is performed [20].
With improvement in technology, development of newer balloons, such as drug-coated bal-
loons (DCB), have significantly improved outcomes in percutaneous interventions of the
peripheral arteries including the SFA disease. Tepe G et al. conducted a randomized controlled
study of 331 patients with symptomatic femoropopliteal artery disease up to 18 cm in length.
At 24 months, outcomes from the trial revealed a durable and superior treatment effect of the
DCB versus percutaneous transluminal angioplasty (PTA) with significantly higher primary
patency, lower clinically driven target lesion revascularization (TLR), and similar functional
status improvement with fewer repeat interventions [21].
Drug-coated balloons have been also studied in complex stenosis such as in-stent restenosis
(ISR). Brodmann et al. performed a study to assess the effectiveness and safety of the use of
paclitaxel-coated drug-coated balloon (DCB) in patients with de novo in-stent restenosis (ISR).
A total of 131 patients were enrolled. Procedural success was achieved in 98.5% of subjects.
Primary patency estimate was 88.7% in the ISR cohort at 12 months. Freedom from clinically
driven target lesion revascularization (CD-TLR) estimated at 92.9% at 12 months [22].
4. Stenting
The efficacy of stenting over the balloon angioplasty failed to show any significant advantage
in the early randomized trials where mainly stainless steel bare-metal stents were used [7, 23,
24]. However, with the advancement in stent technology, further newer studies compared
primary angioplasty to Nitinol stents in the SFA. Interestingly, these studies revealed that
angioplasty alone results in equivalent patency rates when compared to primary stenting in
patients with short lesions. On the other hand, longer stenosis are best treated with primary
stenting and that offers longer time patency (Table 3).
The FAST trial, a multicenter randomized controlled trial, compared the SFA PTA and nitinol
stenting in 244 patients. The indication to treat was claudication in 97% of patients in both
groups. The mean lesion length was relatively short, 4.4 cm in the stenting group and 4.5 cm in
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the PTA group. Results revealed comparable amputation and mortality rates. No significant
differences were noted in the restenosis rates (38.6% in the PTA group vs. 31.7% in the stent
group) or change in clinical status between the two groups. The ankle-brachial index remained
the same at 12 months [25].
The Vienna-ABSOLUTE study was the first randomized study to show superiority of primary
stenting over balloon angioplasty for the treatment of moderate-length SFA lesions, 13.2 cm in
the stenting group, and 12.7 in the PTA group. In this study, 104 patients were included, and
patients were randomized 1:1 to a Dynalink or Absolute stent versus balloon angioplasty. The
indication for treatment was claudication in the majority of cases, 88% in the stent group and
87% in the PTA group. The groups did not defer in limb salvage or mortality. The restenosis
rate was greater in the PTA group (43 vs. 24%, p = 0.05). Duplex ultrasound at 12 months also
demonstrated a greater restenosis rate in the PTA group (63 vs. 37%, p = 0.01). Furthermore, the
maximal walking distance was significantly less in the PTA group at 6 and 12 months (267 vs.
387 m, p = 0.04) [26]. The groups did not defer in limb salvage or mortality. The restenosis rate
was greater in the PTA group (43 vs. 24%, p = 0.05). Duplex ultrasound at 12 months also
demonstrated a greater restenosis rate in the PTA group (63 vs. 37%, p = 0.01). Furthermore, the
Trial Device Sample
size
Average lesion
length (mm)
Primary end point Stent patency
rate %
Bare metal stents
Resiliant
Laird et al. [27]
LifeStent versus PTA 206 71  44 BMS
64  41 PTA
TLR at I year 81/37, 1 year
(p = 0.0001)
FAST
Krachenberk et al.
[25]
Bard Luminexx vs. PTA 244 53.4  29.5
BMS
51.1  24 PTA
Binary restenosis at
1 year
68/62, 1 year
(p = 0.377)
Absolute
Schillinger et al.
[26]
Dynalink/Absolute vs.
PTA
104 132  71 BMS
127  55 PTA
Binary restenosis at
6 months
75/55, 6 months
(p = 0.05)
63/37, 1 year
(p = 0.01)
Drug-eluting stents
SIROCCO I
Duda et al. [34]
Sirolimus coated vs.
SMART
36 82.9 DES
88.6 BMS
In-stent luminal
stenosis at 6 months
100/77, 6 months
(P = 0.10)
SIROCCO II
Duda et al. [55]
Sirolimus coated vs.
SMART
57 86.5  37 DES
76.3  46 BMS
In-stent luminal
stenosis at 6 months
100/93, 6 months
(p = 0.46)
SIROCCO
Long term
Duda et al. [56]
Sirolimus coated vs.
SMART
93 85  44 DES
81  52 BMS
In-stent luminal
stenosis at 6 months
77/79, 2 years
(p > 0.05)
Zilver PTX
Drake et al. [34]
Zilver PTX vs. PTA 479 66.4  38.9
63.2  40.5
Event free survival and
patency
83/33, 1 year
(p < 0.001)
75/27, 2 years
(p < 0.01)
Table 3. Landmark trials for PAD and stenting.
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maximal walking distance was significantly less in the PTA group at 6 and 12 months (267 vs.
387 m, p = 0.04).
Another study that showed significant superiority of stenting versus PTA is the RESILIANT
trial. A multicenter randomized controlled trial (RCT) comparing the PTA to nitinol stenting in
206 patients [27]. Indication for treatment was claudication and the lesion length was in the
moderate range (7.7 cm in the stent group and 6.4 cm in the PTA group). The 6-month primary
patency was worse in the PTA group when compared with primary stenting (47.4 vs. 94.2%,
p = 0.0001). Patients were followed up at 12 months and results remained statistically signifi-
cant in the stenting group (36.7% in the PTA group vs. 81.3% in the stenting group, p = 0.0001).
Even longer term, 3-year follow-up, patients randomized to primary stent placement had
significantly higher freedom from target lesion revascularization (75.5 vs. 41.8%) [28]. The
earlier-mentioned studies provided strong evidence favoring the primary stenting as the
treatment choice for moderate-length SFA lesions.
Based on recent registry studies, current-generation nitinol self-expanding stents have improved
primary patency, with low to zero rates of stent fractures [29, 30]. The SUMMIT study was a
prospective multicenter registry study of the Epic stent, which is a laser-cut nitinol self-
expanding stent [29]. At 1-year follow-up, the restenosis rate was 15.7%, with a freedom from
the target lesion revascularization (TLR) rate of 92%. No stent fractures were noted on follow-up
patients with available X-rays.
COMPLETE SE trial is a prospective multicenter, single-arm study that evaluated the self-
expanding stent in SFA and proximal popliteal for de novo and/or restenotic lesions in patients
with symptomatic PAD [30]. At 1-year follow-up, the primary patency rate was 72.6%, with a
clinically driven.
5. Recent development in SFA stents
Technology continues to undergo significant improvement in SFA stents with the goal to
increase durability and conformability with better long-term patency. The Supera stent (Abbott
Vascular) is a recently approved stent with a novel woven design that results in improved
radial strength, flexibility, and resistance to fracture. The SUPERB study reported a primary
patency rate of 86% in the pivotal registry [31]. Other stent designs under investigation include
the Tigris stent (Gore and Associates), which has a nitinol wire frame with Extended polytetra-
fluoroethylene (ePTFE) coating and interconnecting ePTFE-linking regions. The SMART Flex
stent (Flexible Stent Solutions) has a helical strut bands and flex bridges that provide flexibility
while maintaining longitudinal integrity. The BioMimics 3D stent (Veryan Medical) has a
helical design that may promote laminar flow.
Considering the success of the drug-eluting stents over the bare-metal stents in the coronary
arterial disease, similar stent technology was developed for the peripheral arterial disease
hoping for similar results. Several early studies failed to demonstrate clinical superiority when
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compared to bare-metal stents in the SFA. These early studies included both sirolimus-eluting
and everolimus-eluting designs using an earlier-generation platform [32, 33].
With subsequent development of DES technology, paclitaxel-eluting stent has shown signifi-
cant benefit in the SFA treatment when compared to both balloon angioplasty and placement
of a bare-metal stent. The Zilver-PTX is a nitinol scaffold stent with a polymer-free coating that
elutes paclitaxel [34]. In the ZILVER PTX study, patients were randomized to placement of a
paclitaxel-eluting Zilver stent versus balloon angioplasty. A second arm of the study random-
ized patients to Zilver PTX versus bare-metal stenting in cases of failure of balloon angioplasty.
At 1 year, the primary patency rate was 83% in the DES group versus 32% in the PTA group. In
the second-arm randomization, 1-year primary patency with Zilver PTX was superior to the
Zilver BMS (89.9% vs. 73%). These results showed significant superiority of the Zilver PTX to
both angioplasty alone and the Zilver bare-metal stent (Figures 1 and 2).
Based in the above results, DES use in SFA provides significant promise for improving patency
and long-term outcomes. In the years to come, further improvement in technology of the stent
scaffolds and refinement of drug-eluting technology will further improve outcomes in
endovascular interventions.
Figure 1. There is an example of retrograde approach of the SFA CTO (chronic total occlusion) intervention with PTA and
two Zilver PTA self expanding drug eluting stents (pre intervention).
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6. Atherectomy
Treatment options for the PAD have significantly increased in number, but they remain limited
in scope, as they are lacking substantial scientific data and large-scale randomized trials to help
define the best therapy.
The majority of interventionalists use balloon expansion as a principal therapy which can or
may not be followed by the stenting depending on weather the results of the angioplasty are
satisfactory. This can be associated with vascular barotrauma leading to increase in incidence
of restenosis and the need for re-interventions as the lesions are longer and heavily calcified.
Stent use in SFA disease has shown significant improvement in vessel patency after interven-
tion. [27, 28, 34]. However, the success rate of intervention decreases significantly as the lesions
increase in size of more than 20 cm.
Changing arterial compliance through debulking specifically highly calcified plaques has been
shown to be of benefit. Recent data suggest that atherectomy with or without adjunctive PTA
and/or stenting has shown increased benefit [35].
Figure 2. There is an example of retrograde approach of the SFA CTO (chronic total occlusion) intervention with PTA and
two Zilver PTA self expanding drug eluting stents (post intervention).
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Atherectomy devices remove plaque by physically shaving, drilling, or pulverizing by sanding
the plaque resulting in modification of the vessel and its compliance. Atherectomy usually
causes minimal trauma to the vessel and as such the incidence of acute complications includ-
ing dissection and acute vessel occlusion may be reduced [36].
Initially, atherectomy devices were used in coronary artery disease without much success when
compared to the contemporary bare-metal stents. Potential complication of atherectomy is the
embolization of the debris distally. Shammas NWet al. performed a small study of 40 patients. In
all patient that underwent atherectomy with SilverHawk device macro-embolization occurred.
The study concluded that distal embolic filter protection is very effective in capturing macro
debris and that is associated with good angiographic outcome. To determine the clinical outcome
more randomized controlled studies need to be performed in the future [37].
Currently, there are several atherectomy devices available including directional, rotational,
orbital, and laser atheroablative.
6.1. Laser atheroablative technique
Laser therapy received the FDA approval with the Laser Angioplasty for Critical Limb Ische-
mia (LACI) trial, where a total of 145 patients were enrolled. The diseased segments were
equally distributed involving superficial femoral artery and infrapopliteal segments (41%)
with 15% who had popliteal lesions. In this study, a 308-nm Excimer laser was used to ablate
the plaque and thrombus, restoring the flow in diseased segments. Laser was delivered
through a flexible fiberoptic catheter using short bursts of ultraviolet energy, which vaporized
the plaque into small particles with minimal thermal injury in the surrounding tissues and
lower chance for distal embolization [38].
In the CliRpath Excimer Laser System to Enlarge Lumen Openings (CELLO), Dave RM et al.
evaluated the safety and efficacy of a modified laser catheter designed for the endovascular
treatment of the PAD including the SFA and proximal popliteal artery. The study included 65
patientswith intermediate claudication and stenotic lesion ofmore than 70%byvisual assessment.
Results revealed that laser ablation reduced the diameter stenosis from77% to 34.7%. Patency rates
were 59% and 54% at 6 and 12 months, respectively. There was significant functional status
improvement with increasedwalking distance that was hemodynamically significant [39].
Laser atherectomy has shown to be effective also in patients with in-stent restenosis. Dippel EJ
et al. conducted a multicenter, prospective, randomized controlled trial to assess the safety and
efficacy of the Excimer laser atherectomy (ELA) in addition to PTA alone in patients who
developed in-stent restenosis. The primary efficacy end point was TLR at 6 months follow-up.
The primary safety end point was major adverse event (death, amputation or TLR) at 30-day
post procedure. A total of 250 patient were included in the study, Rutherford class 1–4 and
target lesion length was >4 cm. The lesion length was approximately 20 cm in both groups.
ELA + PTA subjects demonstrated superior procedural success (93.5 vs. 82.7%; p = 0.01) with
significantly fewer procedural complications and less target lesion revascularization (73.5 vs.
51.8%, p < 0.005) [40].
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6.2. Rotational atherectomy
Rotablator system was first used in 1988 and it is currently available as Rotablator System and
consists of an elliptical, nickel-plated, brass burr which is coated with 2000–3000 microscopic
diamond crystals on the leading edge, and the burr rotates at 140,000–190,000 RPM. There are
several available burr sizes available ranging from 1.25 to 2.5 mm. The majority of the debris,
approximately 98%, is smaller than 10 micrometer, which traverses the microvasculature and
is cleared by the reticuloendothelial system [41–43].
Clinical data currently lack any benefit in preventing restenosis in native and restenotic
lesions. Rotational atherectomy is used to prepare a calcified lesion for stenting when a stent
is not deliverable, or it cannot be properly expand [42].
In a single-center Excimer Laser, Rotablator Atherectomy, and Balloon Angioplasty study
(ERBAC), a total of 685 patients were randomized to various atherectomy methods. RA had
the greatest initial success, 89% in RA, 77% in Excimer laser, and 80% in balloon angioplasty.
No differences were observed in major complications at the hospital and at 6 months follow-
up. Revascularization of the original target lesion was performed more frequently in the RA
group (42.4%) and the Excimer laser group (46.0%) than the angioplasty group (31.9%,
p = 0.0013) [44]. Similar results were replicated in a multicenter, prospective trial of 502
patients, Comparison of Balloon Angioplasty versus Rotational Atherectomy in Complex
Coronary Lesions (COBRA) [45].
Pathway Jetstream PV Atherectomy system consists of a single-use catheter with control pod
and a reusable console. The system is indicated for both thrombectomy and rotational
atherectomy. The catheter is advanced over a 0.01400 with a maximum rate of 1 mm/sec to
avoid significant drops in rotational speeds; it has a front-cutting tip that makes it go through
tight lesions. The electric motor spins catheters at 60–70 krpm, and for every 40 sec of treat-
ment, a 10-sec pause is recommended. Jetstream expandable catheters 2.1/3.0 mm and
2.4/3.4 mm have a catheter tip that remains at a defined nominal diameter (2.1 or 2.4 mm)
when spinning clockwise but expands to a maximum diameter when rotating counterclock-
wise. These sizes are recommended for larger-diameter arteries, typically above the knee.
During atherectomy, the device offers a continuous active aspiration [46].
Clinical data are not very robust for the Pathway Jetstream atherectomy device as there are
only small-sized studies performed. The largest study was conducted by Zeller et al. where 172
patients were included with femoropopliteal and popliteal lesions. The success rate was excel-
lent (99%). Patients were followed up at 1 year and the restenosis rate as per arterial duplex
ultrasound was 38.2%. Target lesion revascularization at 6 and 12 months were 15 and 26%,
respectively [47].
6.3. Orbital atherectomy
Orbital atherectomy is an atherectomy device used for plaque modification to reduce the total
atheroma burden, to change the arterial compliance, and to decrease vessel-wall trauma [48].
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The orbital atherectomy device has an eccentrically mounted diamond-coated crown. The
crown sizes include 1.25, 1.5, 2.0, and 2.25 mm. As the crown rotates, the centrifugal forces
press the crown against the calcified lesion that is less compliant, while the healthy segment
complies and moves away from the device reducing the risk for complications such as perfo-
ration. The small particles are so small that distal protection is not necessary. Short and slow
runs are recommended of approximately 1–10 mm/sec to increase the efficacy and reduce the
number of passages. Another advantage of orbital atherectomy over other atherectomy
devices is the bidirectional treatment capability [49].
Clinical evidence for the orbital atherectomy use in peripheral artery disease has been shown
in a serial of studies called CONFIRM registry series. A total of 3135 patient were included
from over 200 centers in the Unites States from October 2009 to June 2011.
Results revealed that treatment with orbital atherectomy (OA) reduced pre-procedural steno-
sis from 88  12% s to an average of 10% with adjunctive treatments, such as low-pressure BA.
Further analysis showed that shorter spin times and smaller crown sizes significantly reduced
procedural complications, which included slow flow, embolism, and spasm [50].
Orbital atherectomy can properly treat a calcified lesion, improving lesion compliance. OA
also increases the luminal gain and by doing so decreases the need for high-pressure balloon
inflation as demonstrated in COMPLIANCE 360trial [51].
6.4. Directional atherectomy
There are two FDA-approved directional atherectomy devices, SilverHawk and TurboHawk.
Both these devices are approved for peripheral vasculature use. SilverHawk is a forward-
cutting directional atherectomy device. The device consists of rotating blade inside a tubular
housing with a collection area. The TurboHawk device is similar in function but has four inner
blades. Both devices come in various sizes to enable atherectomy in vessels with diameters of
1.5–7 mm as the device is advanced and though the lesion plaque is excised and packed in the
nosecone. These devices have the advantages to remove eccentric lesions due to the advantage
of directional control. Distal embolization remains a major disadvantage and the use of distal
protection is recommended, especially in large and heavily plaques.
There is significant clinical data supporting the directional atherectomy devices in peripheral
artery disease. In the TALON registry, a total of 601 patients were included with complaints of
claudication and acute limb ischemia. The procedural success rates were high (over 97%), and
a significant decrease in requirement for stent placement was noted after atherectomy (6.3%).
One-year outcomes correlated well with angioplasty and stenting with free of target lesion
revascularization in the 80% range. Cautious interpretation of the results is advised as this is
an observational registry [52].
A serial of prospective randomized trials were done to assess efficacy of the directional
atherectomy. McKinsey et al. enrolled 275 patients with femoropopliteal disease. Nearly two-
thirds of patients had critical limb ischemia (63%). Limb salvage ischemia was over 90% at 1.5-
year follow-up with a small percentage of patients (4.4%) requiring bypass [53].
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OA efficacy was assessed in critical limb ischemia by Kandzari et al. where 69 patients were
treated and prospectively followed for 6 months. Procedural success rate was very high (99%)
with very low rates of target lesion revascularization (4%) [54].
In conclusion, endovascular therapy has become increasingly common in the treatment of
obstructive SFA disease. With the advance in technology, PAD interventions can be performed
with high success rate and relatively low clinical risk. New-generation drug-eluting stents
have shown very promising results with better long-term patency. However, more random-
ized clinical trials are needed to prove the durability and safety.
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